Insights from Industry RSS Feed - Insights from Industry

'Insights from Industry', a dynamic series of interviews at the cutting edge of the medical industry. Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.
Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Sleep and metabolic disorders: an interview with Professor Bernd Schultes, eSwiss Medical and Surgical Centre, St Gallen, Switzerland

Metabolic disorders are alterations in metabolic processes that can cause harm to a subject. The most common disorders affect the glucose and lipid metabolism causing diabetes and dyslipidemia. Another common disorder is obesity that affects many distinct metabolic processes. [More]
Catheter coating: an interview with Dr. Hinke Malda, Director of Medical Coatings, DSM Biomedical

Catheter coating: an interview with Dr. Hinke Malda, Director of Medical Coatings, DSM Biomedical

DSM’s biomedical work brings new material innovation to market through the development of novel materials-based solutions that meet the present and future needs of the medical device and pharmaceutical industries. [More]
Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

Psychological support for diabetes patients: an interview with Katharine Barnard, University of Southampton

It’s been over a decade since the first Diabetes Attitudes Wishes and Needs (DAWN) study showed that psychosocial aspects of diabetes pose specific challenges and barriers to optimal glycaemic control for people living with diabetes. [More]
miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

RNA interference is a process in which RNA molecules inhibit gene expression. This gene silencing process is controlled by RNA-induced silencing complex or RISC and is initiated by small duplex RNA molecules or miRNA that is present inside cell plasma. [More]
Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Treating advanced cervical cancer: an interview with Dr. Krishnansu Tewari

Cervical cancer affects approximately 500,000 women every year globally of which 250,000 die annually, making it the 2nd leading cause of cancer-related death in women. [More]
New data sharing platform to advance cancer research: an interview with Dr. Charles Hugh-Jones, Chief Medical Officer, Sanofi U.S.

New data sharing platform to advance cancer research: an interview with Dr. Charles Hugh-Jones, Chief Medical Officer, Sanofi U.S.

Project Data Sphere, LLC (PDS) is an independent, not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium (LSC), a group formed by President Bush in 2001 to look at the ways in which different organisations can come together to improve outcomes in cancer research that no individual group could do by itself. The data-sharing platform is one of the projects developed by the group. [More]
Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Continuous glucose monitoring in children: an interview with Terrance Gregg, CEO of Dexcom

Scientific research into CGM-like sensors goes back more than 40 years. I was working with the first company to begin commercial development, MiniMed, back in 1992 when the science was really beginning to percolate. In 1999 the FDA approved the first CGM device for use in the United States. [More]
Safer sharps: an interview with Paul Lindsell, Managing Director, MindMetre

Safer sharps: an interview with Paul Lindsell, Managing Director, MindMetre

In 2010, the European Council described sharps injuries as one of the most serious health and safety threats in European workplaces as an estimated one million injuries were occurring each year. [More]
3D cell culture: an interview with Dr. Elad Katz, Senior Scientist, AMSBIO

3D cell culture: an interview with Dr. Elad Katz, Senior Scientist, AMSBIO

For over fifty years now, we have used 2D cell cultures to culture a variety of cells such as epithelial and blood cells and these are excellent for maintaining cells in their inherent state, under controlled, temperature and other conditions. However, they are limited in preserving the genotype and the phenotype of the original tissue these cells came from. [More]
Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine. [More]
Endogenous tissue growth: an interview with Laurent Grandidier, CEO, Xeltis

Endogenous tissue growth: an interview with Laurent Grandidier, CEO, Xeltis

ETG or Endogenous Tissue Growth is a new therapeutic category in which surgeons use implants designed to allow the body to repair itself by spontaneously growing natural, healthy tissue from the inside without the use of stem cells or animal-derived products. [More]
Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Real-time cervical cancer diagnostics: an interview with Sameer Kothari, Chief Executive of Zilico

Cervical cancer diagnosis is a two-step process. In developed countries, women are invited for a smear test which mainly uses LBC (liquid-based cytology), where a sample of cells are taken from the cervix and sent to a cytopathology lab for analysis. [More]
Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

Non-alcoholic steatohepatitis (NASH): an interview with Jean-François Mouney, CEO of Genfit

The progressive form of Non-Alcoholic Fatty Liver Disease (NAFLD) is Non-Alcoholic Steatohepatitis (NASH), which defines a subgroup of NAFLD where liver steatosis co-exists with cell injury (hepatocyte ballooning) and inflammation with or without fibrosis at histological examination. [More]
Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Rheumatoid arthritis and switching TNFis: an interview with Professor Paul Emery, University of Leeds

Tumor necrosis factor inhibitors (TNFis) are used to treat inflammatory conditions, such as RA. These agents work by blocking TNF, an important mediator of inflammation in RA, in order to help reduce inflammation and stop disease progression. [More]
Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination is a technology that enables the targeted insertion of nucleotide fragments into the genome of a cell. It is called ‘homologous’ because it uses a sequence that is a homologue to the sequence being targeted in a gene, so that the sequence is recognized. [More]
UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

UK waiting times for RA and PsA patients: an interview with Dr Marwan Bukhari, Consultant Rheumatologist at the University Hospitals of Morecambe Bay NHS Foundation Trust

Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation. [More]
Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow. [More]
Nanomedicine – past, present and future: an interview with Frank Boehm, CEO NanoApps Medical Inc.

Nanomedicine – past, present and future: an interview with Frank Boehm, CEO NanoApps Medical Inc.

The fundamental discipline of nanotechnology is poised to change virtually every aspect of our lives, in just about any sector we can think of. [More]
Nanoparticle analysis: an interview with Bernardo Cordovez, CEO of Optofluidics

Nanoparticle analysis: an interview with Bernardo Cordovez, CEO of Optofluidics

Nanoparticle analysis is a very important field. Basically, we live in a world that is immersed in nanoparticles. From the paint we use, to the processes that go on within our very own bodies, nanoparticles play a role and because there are so many nanoparticles everywhere, they need to be analyzed for a variety of reasons. [More]
The future of DNA sequencing: an interview with Barrett Bready, CEO of Nabsys

The future of DNA sequencing: an interview with Barrett Bready, CEO of Nabsys

The first methods for sequencing DNA were developed in the late 1970s. Frederick Sanger developed rapid DNA sequencing methods and published a method for "DNA sequencing with chain-terminating inhibitors,” while Walter Gilbert and Allan Maxam developed "DNA sequencing by chemical degradation". Both methods quickly gained strong followings and were used to sequence a wide variety of DNAs. [More]